$MRNA
144.65 ▲ 0.47% After hours
Every Regards of Wallstreet article on $MRNA, newest first — 4 stories and counting.
2026-08-19 · 10 min read
Moderna Closed Up 177% on the First mRNA Cancer Vaccine Win. The Effect Size Is Still Unpublished
Moderna closed up 176.97% at $174.38 after its Merck-partnered melanoma vaccine met both Phase 3 endpoints, a first for mRNA cancer therapy. The benefit's size is unpublished; buyers assume a large one.
2026-07-31 · 7 min read
Moderna Beat and the Stock Fell. The Whole Company Now Rests on an FDA Decision on August 5
Moderna reported revenue of $145m, above its own guidance and our $103m consensus, and narrowed its loss, then fell on a trimmed outlook. The flu vaccine decision on August 5 is the real event.
2026-07-28 · 5 min read
Moderna Earnings Preview (July 31): Revenue Near $103 Million, and the Only Question Is the Runway
Moderna reports Q2 before the open Friday July 31, call at 8:00am ET, with consensus revenue near $103 million. The stock now trades on cash burn, cost cuts and pipeline.
How has $MRNA traded after past reports? See its earnings history: beats, misses and the moves →
New to options? See our plain-English strategy playbook →
See where $MRNA sits right now on the live S&P 500 heatmap →
The Week-Ahead Brief
Don’t miss next week’s setups. Get the Sunday brief.
Latest issue, Sep 7“Week ahead in the stock market...”
Every Sunday: next week’s earnings dates, Fed days and the trades worth watching, from the same desk that writes the week-ahead hub. Free, built for retail investors.